Assessment of the micronucleus assay as a biological dosimeter using cytokinesis-blocked lymphocytes from cancer patients receiving fractionated partial body-radiotherapy

Simple item page
dc.contributor.authorLe Roux J.
dc.contributor.authorSlabbert J.
dc.contributor.authorSmit B.
dc.contributor.authorBlekkenhorst G.
dc.date.accessioned2011-05-15T16:18:12Z
dc.date.available2011-05-15T16:18:12Z
dc.date.issued1998
dc.description.abstractPurpose: To assess the suitability of the cytokinesis block micronucleus assay as a biological dosimeter following in-vivo radiation using cancer patients undergoing radiotherapy. Methods: Blood from 4 healthy donors was irradiated in vitro with γ-rays and the dose response of induced micronuclei in binucleate lymphocytes following cytokinesis block was determined. Micronucleus frequency was ascertained before and at intervals during radiotherapy treatment in 6 patients with various tumors in the pelvic region. Equivalent whole body doses (physical doses) at these times were calculated from radiation treatment plans and cumulative dose volume histograms. Results: Linear dose response relationships were found for induced micronucleus frequency in lymphocytes resulting from both in-vitro and in-vivo irradiation. Doses resulting from in-vivo irradiation (biological doses) were estimated by substitution of micronucleus frequency observed in radiotherapy patients into the dose response curve from in-vitro irradiation of blood. The relationship between the biologically estimated dose (BD) and the calculated equivalent whole body dose (PD) was BD = 0.868(± 0.043)PD + 0.117(± 0.075). Conclusion: The micronucleus assay appears to offer a reliable and consistent method for equivalent whole body radiation dose estimation, although our findings should be confirmed using lymphocytes from radiotherapy patients with tumors at anatomical sites other than the pelvis. Except at doses lower than about 0.4 Gy, the method yields dose estimates acceptably close to 'true' physically determined doses. The assay can be performed relatively rapidly and can be used as a 'first line' biological dosimeter in situations where accidental exposure to relatively high radiation doses has occurred.
dc.description.versionArticle
dc.identifier.citationStrahlentherapie und Onkologie
dc.identifier.citation174
dc.identifier.citation2
dc.identifier.issn01797158
dc.identifier.urihttp://hdl.handle.net/10019.1/14553
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbladder cancer
dc.subjectcancer radiotherapy
dc.subjectclinical article
dc.subjectcytokinesis
dc.subjectdose response
dc.subjectdosimetry
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectprostate cancer
dc.subjectuterine cervix cancer
dc.subjectAdult
dc.subjectAged
dc.subjectCell Division
dc.subjectCobalt Radioisotopes
dc.subjectDose Fractionation
dc.subjectDose-Response Relationship, Radiation
dc.subjectFemale
dc.subjectHumans
dc.subjectLymphocytes
dc.subjectMale
dc.subjectMicronucleus Tests
dc.subjectMiddle Aged
dc.subjectParticle Accelerators
dc.subjectProstatic Neoplasms
dc.subjectRadiotherapy Dosage
dc.subjectReference Values
dc.subjectUrinary Bladder Neoplasms
dc.subjectUterine Cervical Neoplasms
dc.titleAssessment of the micronucleus assay as a biological dosimeter using cytokinesis-blocked lymphocytes from cancer patients receiving fractionated partial body-radiotherapy
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications